Abstract
A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have